Table 1.
Effects of patient characteristics on death, re-ischemia events and MACE in patients taking AT.
| Characteristics | MACE | Re-ischemia events | Death | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable Analysis | Multivariable Analysis | Univariable Analysis | Multivariable Analysis | Univariable Analysis | Multivariable Analysis | |||||||
| HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Demographic data | ||||||||||||
| Age | 1.021 (1.008–1.035) | 0.0012 | 0.992 (0.976–1.007) | 0.2980 | 1.084 (1.058–1.110) | <0.0001 | 1.054 (1.026–1.083) | 0.0002 | ||||
| Sex (male) | 1.011 (0.752–1.360) | 0.9415 | 0.997 (0.677–1.467) | 0.9859 | 0.988 (0.622–1.568) | 0.9580 | ||||||
| Dosage (mg) | 1.016 (1.000–1.032) | 0.0567 | 1.011 (0.989–1.034) | 0.3369 | 1.024 (1.000–1.048) | 0.0545 | ||||||
| SYNTAX score | 1.031 (1.021–1.040) | <0.0001 | 1.024 (1.013–1.035 ) | <0.0001 | 1.028 (1.015–1.041) | <0.0001 | 1.024 (1.011–1.037) | 0.0004 | 1.035 (1.020–1.050) | <0.0001 | ||
| Medical history | ||||||||||||
| Arrhythmia | 1.684 (1.189–2.384) | 0.0034 | 1.184 (0.695–2.019) | 0.5343 | 2.421 (1.501–3.903) | 0.0003 | ||||||
| Diabetes | 1.702 (1.323–2.190) | <0.0001 | 1.579 (1.128–2.210) | 0.0077 | 2.063 (1.402–3.036) | 0.0002 | ||||||
| Heart failure | 2.720 (1.983–3.731) | <0.0001 | 2.098 (1.463–3.007) | <0.0001 | 2.109 (1.330–3.345) | 0.0015 | 1.829 (1.143–2.926) | 0.0118 | 3.407 (2.161–5.370) | <0.0001 | 2.108 (1.251–3.552) | 0.0051 |
| Hypertension | 1.445 (1.117–1.869) | 0.0050 | 1.681 (1.188–2.379) | 0.0033 | 1.605 (1.132–2.274) | 0.0078 | 1.258 (0.848–1.867) | 0.2542 | ||||
| Hyperlipidemia | 1.256 (0.871–1.811) | 0.2228 | 1.586 (1.024–2.458) | 0.0388 | 1.616 (1.040–2.511) | 0.0328 | 0.707 (0.344–1.455) | 0.3463 | ||||
| Biochemical measurements | ||||||||||||
| ALT, U/L | 1.006 (1.000–1.013) | 0.0646 | 1.007 (0.998–1.016) | 0.1336 | 1.006 (0.995–1.018) | 0.2517 | ||||||
| AST, U/L | 1.002 (0.999–1.005) | 0.1820 | 1.002 (0.997–1.006) | 0.4653 | 1.003 (0.999–1.007) | 0.1566 | ||||||
| CREA, umol/L | 1.009 (1.007–1.012) | <0.0001 | 1.006 (1.003–1.010) | <0.0001 | 1.000 (0.994–1.006) | 0.9702 | 1.016 (1.013–1.018) | <0.0001 | 1.012 (1.008–1.016) | <0.0001 | ||
| eGFR, ml/min/1.73 m2 | 0.991 (0.986–0.996) | 0.0003 | 0.998 (0.995–1.002) | 0.3855 | 0.974 (0.966–0.981) | <0.0001 | ||||||
| CK, U/L | 1.000 (1.000–1.000) | 0.0675 | 1.000 (1.000–1.001) | 0.3281 | 1.000 (1.000–1.001) | 0.0436 | 1 (1.000–1.001) | 0.0015 | ||||
| CKMB, U/L | 1.003 (0.997–1.009) | 0.3043 | 1.001 (0.991–1.011) | 0.8421 | 1.004 (0.996–1.013) | 0.3317 | ||||||
| CHOL, mmol/L | 1.021 (0.916–1.137) | 0.7110 | 1.129 (0.985–1.293) | 0.0806 | 0.838 (0.698–1.007) | 0.0595 | ||||||
| LDLC, mmol/L | 1.000 (0.876–1.142) | 1.0000 | 1.139 (0.965–1.345) | 0.1243 | 0.752 (0.598–0.946) | 0.0147 | ||||||
| HDLC, mmol/L | 0.615 (0.376–1.005) | 0.0526 | 0.815 (0.435–1.529) | 0.5239 | 0.371 (0.166–0.828) | 0.0155 | ||||||
| TRIG, mmol/L | 1.087 (1.001–1.180) | 0.0473 | 1.114 (1.027–1.209) | 0.0092 | 1.101 (0.994–1.220) | 0.0655 | 1.062 (0.924–1.222) | 0.3963 | ||||
| GLUC, mmol/L | 1.055 (1.014–1.099) | 0.0084 | 1.044 (0.988–1.102) | 0.1233 | 1.090 (1.029–1.155) | 0.0034 | ||||||
| Lpa, mg/L | 1.000 (1.000–1.001) | 0.0916 | 1.000 (1.000–1.001) | 0.5121 | 1.001 (1.000–1.001) | 0.0601 | ||||||
| APOA, g/L | 0.491 (0.288–0.836) | 0.0088 | 0.736 (0.382–1.418) | 0.3588 | 0.187 (0.072–0.481) | 0.0005 | 0.258 (0.095–0.703) | 0.0080 | ||||
| Medication | ||||||||||||
| β-blockers | 1.704 (1.056–2.752) | 0.0291 | 3.085 (1.363–6.981) | 0.0069 | 2.608 (1.148–5.924) | 0.0221 | 0.973 (0.534–1.776) | 0.9299 | ||||
| ACEIs | 1.235 (0.952–1.602) | 0.1118 | 1.564 (1.094–2.235) | 0.0141 | 0.953 (0.642–1.414) | 0.8107 | ||||||
| CCBs | 1.341 (1.037–1.735) | 0.0252 | 1.359 (0.970–1.906) | 0.0749 | 1.446 (0.972–2.152) | 0.0686 | ||||||
| PPIs | 1.607 (1.250–2.065) | 0.0002 | 1.446 (1.089–1.919) | 0.0107 | 1.953 (1.394–2.736) | <0.0001 | 1.757 (1.251–2.466) | 0.0011 | 1.221 (0.830–1.794) | 0.3103 | ||
| Plasma concentration | ||||||||||||
| AT, ng/ml | 1.113 (1.003–1.234) | 0.0428 | 1.008 (0.883–1.151) | 0.9013 | 1.356 (1.146–1.605) | 0.0004 | ||||||
| 2-AT, ng/ml | 1.089 (0.967–1.225) | 0.1598 | 0.948 (0.818–1.099) | 0.4782 | 1.388 (1.141–1.688) | 0.0010 | ||||||
| 4-AT, ng/ml | 1.211 (1.092–1.344) | 0.0003 | 1.052 (0.920–1.204) | 0.4584 | 1.548 (1.319–1.816) | <0.0001 | 1.217 (1.017–1.456) | 0.0319 | ||||
| ATL, ng/ml | 1.166 (1.058–1.285) | 0.0019 | 1.069 (0.944–1.211) | 0.2957 | 1.417 (1.211–1.659) | <0.0001 | ||||||
| 2-ATL, ng/ml | 1.200 (1.072–1.343) | 0.0016 | 1.076 (0.933–1.241) | 0.3147 | 1.508 (1.251–1.819) | <0.0001 | ||||||
| 4-ATL, ng/ml | 1.287 (1.157–1.431) | <0.0001 | 1.151 (1.030–1.285) | 0.0128 | 1.161 (1.015–1.328) | 0.0290 | 1.619 (1.361–1.926) | <0.0001 | ||||
Variables with P < 0.05 were entered into the multivariable model, and only variables with P < 0.05 were retained in the model.
2-AT, 2-hydroxy atorvastatin; 2-ATL, 2-hydroxy atorvastatin lactone; 4-AT, 4-hydroxy atorvastatin; 4-ATL, 4-hydroxy atorvastatin lactone; ACEIs, angiotensin converting enzyme inhibitors; ALT, alanine aminotransferase; APOA, apolipoprotein a; AST, aspartate aminotransferase; AT, atorvastatin; ATL, atorvastatin lactone; CCBs, calcium channel blockers; CHOL, cholesterol; CK, creatine kinase; CKMB, creatine kinase MB; CREA, creatinine; eGFR, estimated glomerular filtration rate; GLUC, glucose; HDLC, high-density lipoprotein cholesterol; HR, hazard ratio; LDLC, low-density lipoprotein cholesterol; Lpa, lipoprotein (a); MACEs, major adverse cardiovascular events; PPIs, proton pump inhibitors; SD, standard deviation; TRIG, triglyceride.